Cargando…

Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals

BACKGROUND: Cystic fibrosis (CF) is a genetic condition caused by variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that primarily impacts the lungs. Treatments historically have been symptomatic to improve airway clearance and treat infection. However, CFTR modulator d...

Descripción completa

Detalles Bibliográficos
Autores principales: Almulhem, Maryam, Harnett, Nuala, Graham, Stephanie, Haq, Iram, Visram, Shelina, Ward, Christopher, Brodlie, Malcolm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557266/
https://www.ncbi.nlm.nih.gov/pubmed/36207030
http://dx.doi.org/10.1136/bmjresp-2022-001420
_version_ 1784807266998812672
author Almulhem, Maryam
Harnett, Nuala
Graham, Stephanie
Haq, Iram
Visram, Shelina
Ward, Christopher
Brodlie, Malcolm
author_facet Almulhem, Maryam
Harnett, Nuala
Graham, Stephanie
Haq, Iram
Visram, Shelina
Ward, Christopher
Brodlie, Malcolm
author_sort Almulhem, Maryam
collection PubMed
description BACKGROUND: Cystic fibrosis (CF) is a genetic condition caused by variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that primarily impacts the lungs. Treatments historically have been symptomatic to improve airway clearance and treat infection. However, CFTR modulator drugs have recently been developed that target the underlying defect. The triple combination of elexacaftor-tezacaftor-ivacaftor (ETI) was approved in 2020 in England for over 80% of people with CF aged over 12 years and in 2022 extended to those over 6 years. ETI treatment is associated with substantial improvements in lung function. The experience of children with CF starting on ETI or their views regarding future treatments have not been well studied. This study aimed to explore the opinions of children with CF, their parents/carers and healthcare professionals (HCPs) on the impact of ETI, airway clearance techniques (ACTs) and nebulised treatments. METHODS: Semistructured qualitative interviews were performed with 10 children with CF, 7 parents/carers and 10 HCPs. Audio recordings were transcribed and analysed using reflexive thematic analysis. RESULTS: Four main themes were identified: ‘Kaftrio changed my life’, ‘Your entire life is dictated by the CF timetable’, ‘Simplifying treatment-hopes and fears’ and ‘Kaftrio is a game-changer’ along with several subthemes and an overarching theme of ‘I still can’t get my head around how three tablets can do what Kaftrio done’. CONCLUSIONS: Despite the highly positive impact of ETI on the health of children with CF some concerns remain about the longer-term outcomes of reducing ACTs or nebulised treatments. ETI has prompted a shift in treatment for many and offers an opportunity to personalise approaches.
format Online
Article
Text
id pubmed-9557266
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-95572662022-10-14 Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals Almulhem, Maryam Harnett, Nuala Graham, Stephanie Haq, Iram Visram, Shelina Ward, Christopher Brodlie, Malcolm BMJ Open Respir Res Cystic Fibrosis BACKGROUND: Cystic fibrosis (CF) is a genetic condition caused by variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that primarily impacts the lungs. Treatments historically have been symptomatic to improve airway clearance and treat infection. However, CFTR modulator drugs have recently been developed that target the underlying defect. The triple combination of elexacaftor-tezacaftor-ivacaftor (ETI) was approved in 2020 in England for over 80% of people with CF aged over 12 years and in 2022 extended to those over 6 years. ETI treatment is associated with substantial improvements in lung function. The experience of children with CF starting on ETI or their views regarding future treatments have not been well studied. This study aimed to explore the opinions of children with CF, their parents/carers and healthcare professionals (HCPs) on the impact of ETI, airway clearance techniques (ACTs) and nebulised treatments. METHODS: Semistructured qualitative interviews were performed with 10 children with CF, 7 parents/carers and 10 HCPs. Audio recordings were transcribed and analysed using reflexive thematic analysis. RESULTS: Four main themes were identified: ‘Kaftrio changed my life’, ‘Your entire life is dictated by the CF timetable’, ‘Simplifying treatment-hopes and fears’ and ‘Kaftrio is a game-changer’ along with several subthemes and an overarching theme of ‘I still can’t get my head around how three tablets can do what Kaftrio done’. CONCLUSIONS: Despite the highly positive impact of ETI on the health of children with CF some concerns remain about the longer-term outcomes of reducing ACTs or nebulised treatments. ETI has prompted a shift in treatment for many and offers an opportunity to personalise approaches. BMJ Publishing Group 2022-10-07 /pmc/articles/PMC9557266/ /pubmed/36207030 http://dx.doi.org/10.1136/bmjresp-2022-001420 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Cystic Fibrosis
Almulhem, Maryam
Harnett, Nuala
Graham, Stephanie
Haq, Iram
Visram, Shelina
Ward, Christopher
Brodlie, Malcolm
Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals
title Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals
title_full Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals
title_fullStr Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals
title_full_unstemmed Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals
title_short Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals
title_sort exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: tempo a qualitative study in children with cystic fibrosis, their families and healthcare professionals
topic Cystic Fibrosis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557266/
https://www.ncbi.nlm.nih.gov/pubmed/36207030
http://dx.doi.org/10.1136/bmjresp-2022-001420
work_keys_str_mv AT almulhemmaryam exploringtheimpactofelexacaftortezacaftorivacaftortreatmentonopinionsregardingairwayclearancetechniquesandnebuliserstempoaqualitativestudyinchildrenwithcysticfibrosistheirfamiliesandhealthcareprofessionals
AT harnettnuala exploringtheimpactofelexacaftortezacaftorivacaftortreatmentonopinionsregardingairwayclearancetechniquesandnebuliserstempoaqualitativestudyinchildrenwithcysticfibrosistheirfamiliesandhealthcareprofessionals
AT grahamstephanie exploringtheimpactofelexacaftortezacaftorivacaftortreatmentonopinionsregardingairwayclearancetechniquesandnebuliserstempoaqualitativestudyinchildrenwithcysticfibrosistheirfamiliesandhealthcareprofessionals
AT haqiram exploringtheimpactofelexacaftortezacaftorivacaftortreatmentonopinionsregardingairwayclearancetechniquesandnebuliserstempoaqualitativestudyinchildrenwithcysticfibrosistheirfamiliesandhealthcareprofessionals
AT visramshelina exploringtheimpactofelexacaftortezacaftorivacaftortreatmentonopinionsregardingairwayclearancetechniquesandnebuliserstempoaqualitativestudyinchildrenwithcysticfibrosistheirfamiliesandhealthcareprofessionals
AT wardchristopher exploringtheimpactofelexacaftortezacaftorivacaftortreatmentonopinionsregardingairwayclearancetechniquesandnebuliserstempoaqualitativestudyinchildrenwithcysticfibrosistheirfamiliesandhealthcareprofessionals
AT brodliemalcolm exploringtheimpactofelexacaftortezacaftorivacaftortreatmentonopinionsregardingairwayclearancetechniquesandnebuliserstempoaqualitativestudyinchildrenwithcysticfibrosistheirfamiliesandhealthcareprofessionals